Toceranib

Toceranib is a receptor tyrosine kinase inhibitor and is used in the treatment[1] of canine mast cell tumor also called mastocytoma. Together with masitinib (Kinavet (US)/Masivet (EU/ROW) by AB Science), toceranib is the only dog-specific anti-cancer drug[2] approved by the U.S. Food and Drug Administration.[3] It is marketed as Palladia as its phosphate salt, toceranib phosphate (INN) by Pfizer. It was developed by SUGEN as SU11654,[4] a sister compound to sunitinib, which was later approved for human therapies. Toceranib is likely to act mostly through inhibition of the kit tyrosine kinase, though it may also have an anti-angiogenic effect.

Toceranib
Clinical data
Trade namesPalladia
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Oral
ATCvet code
Legal status
Legal status
Pharmacokinetic data
Bioavailability77%
Protein binding91%-93%
Elimination half-life16 h
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H25FN4O2
Molar mass396.46 g/mol
494.46 g/mol (phosphate) g·mol−1
3D model (JSmol)

References

  • "Toceranib". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.